Phase 3 Crohn's Disease and Colitis Trial, Recruiting NCT06332534 Sponsor: AbbVie Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 3 Crohn's Disease and Colitis Trial, Recruiting

NCT06332534
Recruiting Phase 3 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You weigh at least 10 kg (about 22 pounds) at the time of screening and at the start of the trial.
  • You have been diagnosed with moderate to severe Crohn's Disease in children or teens, confirmed by specific activity scores and a camera examination of the gut (colonoscopy) showing inflammation.
  • Your Crohn's Disease diagnosis has been confirmed by colonoscopy during the screening period, with biopsy results supporting the diagnosis, and with no signs of current infection or abnormal/cancerous cells in the colon.
  • Previous treatments (such as steroids, immune-suppressing medicines, or biologic therapies) have not worked well enough for you, stopped working, caused intolerance, or cannot be used for medical reasons. (Note: if you are in the US or South Korea, you must specifically have had an inadequate response, loss of response, or intolerance to at least one anti-TNF biologic medication.)

Who may not be able to join:

  • You were first diagnosed with Crohn's Disease before the age of 2.
  • You currently have an active abscess (a pocket of infection) in the abdomen or around the back passage.
  • You currently have bowel blockages causing symptoms.
  • More than 2 out of 5 specific sections of your intestine are missing.
  • You have a stoma (ostomy bag) or an internal pouch connected to your bowel.
  • You have had bowel surgery in the last 3 months, or more than 3 bowel surgeries in total.
  • You are participating in Japan and have a positive or repeatedly unclear test result for a specific fungal infection screening (confirm with trial site).
  • You currently have ulcerative colitis, indeterminate colitis, or a rare inherited form of inflammatory bowel disease.
  • You have a history of a severe, rapidly worsening bowel condition called fulminant colitis or toxic megacolon.
  • You have had a hole (perforation) develop in your gut (unless caused by appendicitis or a physical injury), a history of diverticulitis, or other conditions that significantly raise the risk of gut perforation, such as a history of the bowel twisting or telescoping.
  • You currently have any condition where your immune system does not work properly from birth (primary immune deficiency).
  • You have a condition that affects how your body absorbs medicines, such as short bowel syndrome or a history of gastric bypass surgery. (Note: a history of gastric banding alone does not exclude you — confirm with trial site.)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: ABBVIE INC., AbbVie

Phone: 844-663-3742

Australian sites

Sydney Children's Hospital /ID# 262352, Randwick, New South Wales
Children's Hospital at Westmead /ID# 262350, Westmead, New South Wales
Queensland Children's Hospital /ID# 262351, South Brisbane, Queensland
Monash Health - Monash Medical Centre - Clayton /ID# 262878, Clayton, Victoria
Perth Children'S Hospital /ID# 272905, Perth, Western Australia

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
8 August 2024
Est. completion
1 June 2027

Where this trial is recruiting

🇦🇺 Australia 🇧🇪 Belgium 🇧🇷 Brazil 🇧🇬 Bulgaria 🇨🇦 Canada 🇨🇳 China 🇫🇷 France 🇬🇷 Greece 🇮🇹 Italy 🇯🇵 Japan 🇳🇿 New Zealand 🇵🇱 Poland Puerto Rico 🇰🇷 South Korea 🇪🇸 Spain 🇹🇼 Taiwan 🇬🇧 United Kingdom 🇺🇸 United States

5 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Percentage of participants who achieved clinical response per the Pediatric Crohn's Disease Activity Index (PCDAI) at Week 12, with clinical remission per the PCDAI at Week 64; Achievement of endoscopic response at Week 64 in participants who achieved clinical response per PCDAI at Week 12.; Number of Participants with Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov